

Datasheet: HCA211

BATCH NUMBER 168398

Description:	HUMAN ANTI USTEKINUMAB
Specificity:	USTEKINUMAB
Other names:	Stelara®
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	AbD17829_hlgG1
Isotype:	IgG1
Quantity:	0.1 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form	Human IgG1 antibody selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
Preparation	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Source	HKB-11
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃)
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml

Immunogen	Ustekinumab
Specificity	<p>Human Anti-Ustekinumab Antibody, clone AbD17829_hlgG1 is a paratope specific, anti-idiotypic antibody that specifically recognizes the monoclonal antibody drug ustekinumab and inhibits binding to its target.</p> <p>Clone AbD17827_hlgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator in an anti-drug antibody (ADA) assay.</p> <p>Ustekinumab (Stelara) is a fully human monoclonal antibody drug (IgG1/kappa) that has been approved in US, Canada, and Europe for the treatment of plaque psoriasis and psoriatic arthritis. The FDA approved the medication for the treatment of moderate-severe Crohn's disease in 2016. The drug blocks interleukin IL-12 and IL-23 by binding with high affinity and specificity to the p40 subunit, preventing the binding of these two cytokines to T-lymphocytes, and thereby disrupting the proinflammatory pathway.</p> <p>View a summary of all anti-ustekinumab antibodies</p>
Affinity	The monovalent intrinsic affinity of AbD17829 is $K_D = 2.8$ nM as measured by real time, label free molecular interaction analysis on immobilized ustekinumab.
ELISA	<p>This product may be used in an indirect ELISA or as a detection antibody when conjugated to HRP in a bridging ELISA together with AbD18334 (HCA209) as the capture reagent. Conjugation of this antibody to HRP can be undertaken using a Lynx Rapid HRP conjugation kit, these kits may be purchased from Bio-Rad.</p> <p>Protocol: PK bridging ELISA to measure free drug.</p>
Storage	<p>This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.</p> <p>Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.</p>
Guarantee	12 months from date of despatch
Acknowledgements	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Health And Safety Information	Material Safety Datasheet documentation #10040 available at: https://www.bio-rad-antibodies.com/SDS/HCA211 10040
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.

Regulatory For research purposes only

Technical Advice Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the [HuCAL Antibodies Technical Manual](#).

Related Products

Recommended Useful Reagents

- [LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK001P\)](#)
- [LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)
- [LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK003P\)](#)
- [LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK004P\)](#)
- [LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK005P\)](#)
- [LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK006P\)](#)

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M428364:240301'

Printed on 23 May 2024

© 2024 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)